Peer Review History
| Original SubmissionApril 30, 2022 |
|---|
|
PONE-D-22-12723The Reality of Embedded Drug Purchasing Practices: Understanding the Sociocultural and Economic Aspects of the Use of Medicines in BangladeshPLOS ONE Dear Dr. Miah, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
Please submit your revised manuscript by Aug 24 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Mary Hamer Hodges, MBBS MRCP DSc Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. During our internal checks, the in-house editorial staff noted that you conducted research or obtained samples in another country. Please check the relevant national regulations and laws applying to foreign researchers and state whether you obtained the required permits and approvals. Please address this in your ethics statement in both the manuscript and submission information. In addition, please ensure that you have suitably acknowledged the contributions of any local collaborators involved in this work in your authorship list and/or Acknowledgements. Authorship criteria is based on the International Committee of Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts Submitted to Biomedical Journals - for further information please see here: https://journals.plos.org/plosone/s/authorship. 3. Thank you for stating the following financial disclosure: “Yes partial for conducting the fieldwork but the funder have no role in study design, data collection and analysis, decision to publish or preparation of the manuscript” At this time, please address the following queries: a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” c) If any authors received a salary from any of your funders, please state which authors and which funders. d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 4. Thank you for stating the following in your Competing Interests section: “None” Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now This information should be included in your cover letter; we will change the online submission form on your behalf. 5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 7. Please include a copy of Table 1 which you refer to in your text on page 8. Additional Editor Comments: You study is of interest and importance especially for Low Income Countries. However, as pointed out by the reviewer there are major revisions required in the presentation and interpretation of results. I recommend a thorough revision dealing which each comment before considering re submission to PLOS ONE. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Comments This article explored an interesting and important aspects of drug purchasing practices in Bangladesh. However, one of the important flaws of this paper it tries to emphasis the vague quantitative findings through qualitative method without taking into account any quantitative factors. I would suggest the author to focus on the findings on the reasons why this practices rather than emphasizing on the 30 background factors e.g., Income, education, cultural beliefs, confidence in sellers, among others to make a conclusion. Abstract 1. The author mentioned that “This study explores patterns of drug purchasing which underlie the socio-cultural and economic aspects of a Bangladeshi city”. How is it feasible to explore pattern through a qualitative study? 2. The results seemed to be vague quantitative findings without any specific numbers. Background 1. Line 46: “….aggressive competition among the drug firms” this should be supported by evidence. 2. Line 52: “Moreover, every year, US$ 42 billion is spent on the inappropriate use of drugs” Where? 3. Line 73: “For most patients in developing countries like Bangladesh…. what proportion? Any information? 4. Line 88: ““access to safe, effective, quality and affordable medicines and vaccines for all”” I do not understand how the author has linked "access" with the context of current manuscript. Is this author meant the availability of quality drugs? If yes, is availability of quality drugs in pharmacy is similar to access? My understanding is that ‘access’ is determined by various socioeconomic factors and different from availability. 5. Line 97: is not clear. What the author meant by density? Per facility? 6. Line 99: “Following field study techniques of organizing complex research subjects and data, three topics were chosen as collection tools, namely 'places, people, and events.” Should be supported by evidence of where this technique has been used? 7. Line 186-187: “The opening hours of these drug stores were between 8.00 am and 10.am, however, they visited customers at home in an emergency.” This line is not clear. What the author wanted to mean here? 8. Line 181: the author mentioned that “three different drug stores were selected from three different settings?” It is not clear how the author determined different settings in terms of what? and why the author have chosen three different settings? 9. Line 195: author mentioned that “Customers’ drug purchasing behavior was influenced by demographic factors such as income, education, cultural beliefs and social network of the community people.” it is predictable that these socioeconomic factors influence customers’ drug purchasing behavior. However, what is new here? It would be useful to identify to what extent which factors affect the behaviour of the consumers? Otherwise, this statement remains vague, and dose not add anything to the findings. I assume this may not be possible to quantify this finding from only 30 interviews. I would recommend author not to focus on only the factors those affect the consumer drug purchasing behavior rather identify the key reasons for the identified behavior. 10. Line 196: “Those living in wealthier areas mostly bought prescription and trade name drugs” I do not see any calculation of wealth quintile. How the author concluded this is not clear. A clear representation of the calculation of wealth quintile should be presented. Or on what criterion the author divided the respondents into different socioeconomic group should be mentioned clearly. 11. Line 207-208: please see comment 09. 12. Line 225: “customer’s individual choices” I am not sure how the author determined the choices of consumer? Did the author wanted to mean their previous behaviour of drug purchasing? 13. Line 246: “In addition, the customer also seeks to buy a package of expensive drugs by instalment payments as well as by buying recommended drugs and those for a particular ailment.” This finding is interesting. However, the author ha not mentioned what is the understanding between the consumer and the drug seller regarding EMI? How the expensive drugs will be sold to consumers in EMI without any guarantee of repayment by the consumers? 14. Line 252: “around $3 @ 85 takas per $” The author should mention which dollar they rereferred to. 15. Line 278: “Findings revealed that some unregistered local drugs were dispensed and sold in the drug store.” I think it is difficult to conclude this finding from information from only three drug stores. 16. Line 406: “patient preference” the preference is a technical term, which should be assessed as revealed or stated. I would rather suggest the author to use behavior instead of preference. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-22-12723R1The Reality of Embedded Drug Purchasing Practices: Understanding the Sociocultural and Economic Aspects of the Use of Medicines in BangladeshPLOS ONE Dear Dr. Md. Shahgahan Miah, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Mar 02 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Dr Haribondhu Sarma, PhD Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Apologies for taking the time to review your paper. Unfortunately, there is a limited number of reviewers who have the expertise and interest to review this paper. We have reviewers who initially agreed but later did not complete the review on time. I reviewed your paper and have following comments: This is an interesting and important study that investigated the drug purchasing practices which underlie the socio-cultural and economic aspects of a Bangladeshi city. However, there are a few areas in the manuscripts that can be further improved considering my additional comments. I have following minor observations, please consider them while revising it: 1. In the first sentence of the abstract, please replace the word ‘standard’ with ‘common’. Please note that purchasing drugs with or without a prescription from retail drug shops is NOT a standard practice in Bangladesh, but it may be a common practice. 2. Please add a sentence under the results of the abstract with the number of IDIs, KIIs and observations you have conducted. 3. In your first revision, you did not highlight the texts in which you have made changes. Please do so in your next revision. 4. Line 77, please define what it means about ‘C’ grade pharmacists. 5. Line 190, please check again the time of the opening hours, whether it is 8.00 AM to 10.00 PM? 6. Please confirm whether the study has been approved by any local ethics committee. [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
PONE-D-22-12723R2The Reality of Embedded Drug Purchasing Practices: Understanding the Sociocultural and Economic Aspects of the Use of Medicines in BangladeshPLOS ONE Dear Dr. Md. Shahgahan Miah, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ACADEMIC EDITOR: Minor Revision Please provide a final paper with all revisions made and with an additional check on the level of plagiarism and compliance with the editorial Journal's guidelines. Please submit your revised manuscript by May 21 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Vincenzo Basile, PhD Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: N/A ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Many thanks for addressing the earlier comments, I have some further comments and suggestions attached in the mansucript. Reviewer #2: PONE-D-22-12723R2 review The manuscript outlines a qualitative research study that explores drug seller and drug purchaser perspectives in Bangladesh. As I have stated, below, in my comments to the authors, literature on the topic from Bangladesh has not be explored and therefore there is overlap with previous findings. The authors need to revise their literature review and re-frame the introduction. This will allow the authors to focus on new findings rather than be repetitive of previous qualitative studies conducted in Bangladesh. I have added some papers for consideration but this is in no way exhaustive, just the ones with which I have some familiarity. There are several comments on improving the English expression and adding more detail to improve manuscript clarity. Because there are new findings that are worth highlighting, I think that the manuscript may be appropriate for publication after a significant revision. Abstract Line 22: are medical representatives pharmaceutical company employees? Please provide a more intuitive description to the international reader. Line 23: nonverbal behaviour is a vague term. Add some specifics. The next sentence implies that a single participant was selected. Please revise this and indicate the total number. Line 28: use the active voice. You are describing the results overall here. So, starting a sentence with 'results revealed' is not informative. In qualitative studies it is useful to include the type of data collection method that the results were drawn from. Do you mean 'We detected that xxxxxx from IDI thematic content analysis?' Line 29: this sentence contradicts the first. You mean to describe the range of intentions of the customers. Revise the English expression to reflect this. Line 31: it would be more useful to include at least one cultural belief. Using the term 'cultural belief' is vague and general. Line 35: It is impossible to determine which were common versus rare behaviours. A semi-quantitative approach would be more meaningful. Some, most, many (with number of respondents) is often used in qualitative studies to indicate common vs. rare behaviour. Line 37: the conclusion does not follow from the findings included in the results section. Be specific about what the findings can tell policy makers. This conclusion could have been written without conducting the study. Introduction Line 86: I disagree that there is little research on sociocultural and economic factors that contribute to economic aspects of drug purchasing. Quite a bit has been done on antibiotic purchasing alone, in Asia (including Bangladesh) and Africa, among others. A more detailed literature review is needed. This probably should have been done before developing IDI question guidelines. Line 90: change 'gather' to 'gathered', Methods Line 109: it is known that different types of customers visit at different times of the day. Please provide some information on timing of preliminary observations. Line 118: Since there were only three outlets, I am assuming that the authors mean 'one each of a seller with limited training, a RMP and a trainee sales assistant. Line 122: this information should be in the results, not methods. Line 129: please provide the number of each participant type. Line 130: by primary healthcare providers with drug sellers, do you mean doctors that have a room in the drug shop?? Line 141: For an international audience, some context or photo of what comprises a drug shop in Bangladesh would be useful. For many in the Western world, they think this means a fully heated/air-conditioned 'pukka' premise with tiled floors etc. Line 146: what questions examined economic situations of the participants? This is a finding that you have described. Was affordability a topic that came up without a prompt? Line 148: what do you mean by local cultural drug purchasing? Line 149: as indicated for the abstract, define what is meant by non-verbal interactions (note that this is in the manuscript both with and without a hyphen- ensure consistency throughout) Line 154: what is meant by 'member checking'. Ethical issues: it is uncommon for a study conducted in Bangladesh to not receive any local ethical approval. That form another country is often considered inadequate. Results Table 1: Omit the first sentence. Start with the total number of participants then briefly describe their characteristics without repeating all of the data in the table. some numbers are in bold and others not. I don't see a consistent pattern. were there no data on where the key informants resided? I think that a lay patient is just a patient. age 45+/-9 seems to be in the wrong column for education, it would be better if the year categories lined up for IDI and KII Line 195: approximate or typical closing hours would be useful to include. Line 203: It is difficult to determine whether behaviours described here and elsewhere in the manuscript were self-reported during IDIs or observed by researchers or both. Line 205: The new sentence starting here should be part of a new paragraph. This information is about socioeconomic differences. Table 2: this is a description of the drug stores. Change the title to reflect this. Since there are only three drug stores (sometimes called retail drug shops, drug shops- be consistent throughout the manuscript), it should be 'slum area' rather than 'slum areas'. It's not clear where the data in this table were derived from. Drug shop staff or customers or both? change common health problem to commonly reported health problem. change 'selling products' to 'products sold'. Were these data from customers or drug shop staff or both. Line 214 'Practices of' can be deleted. Line 216: this reads as if there is one individual. Fix the English. Line 218: Make the distinction between drugs for chronic conditions such as diabetes, hypertension etc and drugs for acute conditions e.g. infections. This is an important distinction. Line 233: was this behaviour restricted to the slum dwellers or those visiting drug shop 2 only? It seems to be a common behaviour. Line 250: include whether this was the case for all drug shops. Line 283": this is not a good quotation. flucloxacillin is the name of the drug in fluclox'. Line 293: do the authors mean the drug stores in the slum or the drug stores in the slum. Fix the English. Line 296: remove the word 'of'. Line 300: this is an interesting finding that drug sellers feel more comfortable to recommend unregistered drugs to those from lower SES groups. It's worth including in the discussion. Line 304: omit the phrase 'from the drug store’. Also omit 'Data revealed that the' Line 308: do the authors mean that these data came from drug shop observations? I have not seen any reference to findings from this data collection exercise up to this point in the manuscript. line 320: circumcision is not just a procedure used by Muslims. It is also conducted by people from other religious groups and those without religious conviction. There's no need to describe this as a religious ritual. Line 325: excellent quote. Line 329: research data don't report, participants do. Fix this throughout. There are examples of ‘data showed’, results revealed etc. that need the expression revised. Line 340: similarly use the active voice 'we found that customers often visited....... Line 344: in the methods, the authors describe that observations are for detecting non-verbal interactions. Line 346: there is a quotation mark missing. It should probably go after 'what should I do'. Line 357: Competition to achieve a reputation for successful treatment: This business aspect of drug stores is well worth highlighting. Little attention is given to economic factors from the supply side. Often suggestions for antibiotic stewardship improvements, for example, assume that the supply side has bad motives. There’s nothing wrong in working to make a business thrive. I did not find results on non-verbal interactions. Discussion The opening sentence is incorrect. See the following papers: 1. Lucas PJ, Uddin MR, Khisa N, Akter SMS, Unicomb L, Nahar P, Islam MA, Nizame FA, Rousham EK. Pathways to antibiotics in Bangladesh: A qualitative study investigating how and when households access medicine including antibiotics for humans or animals when they are ill. PLoS One. 2019 Nov 22;14(11):e0225270. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0225270 2. Nahar P, Unicomb L, Lucas PJ, Uddin MR, Islam MA, Nizame FA, Khisa N, Akter SMS, Rousham EK. What contributes to inappropriate antibiotic dispensing among qualified and unqualified healthcare providers in Bangladesh? A qualitative study. BMC Health Serv Res. 2020 Jul 15;20(1):656 3. Nizame FA, Shoaib DM, Rousham EK, Akter S, Islam MA, Khan AA, Rahman M, Unicomb L. Barriers and facilitators to adherence to national drug policies on antibiotic prescribing and dispensing in Bangladesh. J Pharm Policy Pract. 2021; 14(Suppl 1): 85. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594093/ 4. Matin MA, Khan WA, Karim MM, Ahmed S, John-Langba J, Sankoh OA, Gyapong M, Kinsman J, Wertheim H. What influences antibiotic sales in rural Bangladesh? A drug dispensers' perspective J Pharm Policy Pract. 2020 Jun 3;13:20. Revise the first paragraph accordingly. Also, from these papers, determine what is new and novel about the data presented in the current manuscript. The first paragraph states that ‘new aspects’ were detected, which suggests that the authors are familiar with other work on this topic. This may possibly be from other countries. Nevertheless, it somewhat contradicts the opening sentence. Line 379: this sentence is vague. Point to the results that support this sentence, which should probably be broken into two or more parts. Line 387: this sentence is also not true, since there are published findings from Bangladesh and elsewhere that have reported this. Line 399: I think this is a citation which is a superscript rather than in parentheses. Line 403: this is new data that was not included in the results section. Move to results. Line 434: purposive sampling is not a limitation but a standard qualitative technique. Conclusion: see the comment for the conclusion section in the abstract. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 3 |
|
The Reality of Embedded Drug Purchasing Practices: Understanding the Sociocultural and Economic Aspects of the Use of Medicines in Bangladesh PONE-D-22-12723R3 Dear Dr. Md. Shahgahan Miah, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Vincenzo Basile, PhD Academic Editor PLOS ONE Additional Comments: Please provide a final paper with all revisions made and I recommend an additional check on plagiarism and/or compliance with the Journal's guidelines. |
| Formally Accepted |
|
PONE-D-22-12723R3 The Reality of Embedded Drug Purchasing Practices: Understanding the Sociocultural and Economic Aspects of the Use of Medicines in Bangladesh Dear Dr. Miah: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Vincenzo Basile Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .